# Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

> **NCT06317051** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Kirby Institute** · enrollment: 300 (estimated)

## Conditions studied

- HIV Infections
- Weight Gain

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Pitavastatin 4 Mg Oral Tablet
- **DRUG:** Rosuvastatin and Ezetimibe
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06317051
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317051, "Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06317051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*